# Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors

> **NCT02581384** · PHASE1,PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 5 (actual)

## Conditions studied

- Ewing Sarcoma
- Rhabdomyosarcoma
- Wilms Tumor
- Osteosarcoma
- Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Nos
- Renal Tumor
- Rhabdoid Tumor
- Clear Cell Renal Cell Carcinoma
- Sarcoma
- Sarcoma, Ewing
- Soft Tissue Sarcoma

## Interventions

- **RADIATION:** Stereotactic Body Radiotherapy (SBRT)

## Key facts

- **NCT ID:** NCT02581384
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01
- **Primary completion:** 2020-08
- **Final completion:** 2020-08
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The study closed primarily due to weak accrual, as well as study design limitations.
- **Last updated:** 2021-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02581384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02581384, "Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02581384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*